[November 14, 2014]

Research and Markets: Global Antibody Drug Conjugate Market Outlook 2018 Edition

Research and Markets (http://www.researchandmarkets.com/research/9d5m45/global_antibody) has announced the addition of the "Global Antibody Drug Conjugate Market Outlook 2018 Edition" report to their offering.

According to our report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC (News - Alert) market is anticipated to reach around US$ 3 Billion by 2018.

For more than a century, the concept of a magic bullet to deliver cytotoxic therapy to the site of tumor has been envisioned, but only recently the technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of ADCETRIS and Kadcyla followed by various ADCs in pipeline highlight the potential for new therapeutic innovations in ADC industry.

The report also provides an insight into the key ADCs that are in advanced stage of trial, with Glematumumab vedotin (Anti-GPNMB ADC) as one of the examples. Further, the report highlights the ADCs with respect to the type of cancer targeted, and drugs used. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place in the ADC space have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones, for the development of ADCs.

Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs, difficult upstream and downstream processing, safety considerations, etc., will have to be taken care of.

At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2018

5. ADC Pipeline Analysis

6. Current Status of Potential ADCs in Pipeline

7. Strategic Collaborations in the ADC Industry

8. Drivers and Challenges

9. Competitive Landscape

Companies Mentioned

- Agensys, Inc.

- Immunogen, Inc.

- Immunomedics

- Roche

- Seattle Genetics

For more information visit http://www.researchandmarkets.com/research/9d5m45/global_antibody

[ Back To TMCnet.com's Homepage ]